Skip to main content
. 2018 Oct 10;9:2319. doi: 10.3389/fimmu.2018.02319

Figure 6.

Figure 6

The formulation of OVA/CpG-ODN with Coa-ASC16 enhances in vivo co-uptake of OVA and CpG-ODN by DCs. C57BL/6 mice were immunized in both hind limbs with Alexa Fluor 647-OVA/Alexa Fluor 488-CpG-ODN or Alexa Fluor 647-OVA/Alexa Fluor 488-CpG-ODN/Coa-ASC16. Seventy-two h later, cell suspension from inguinal LN were analyzed by flow cytometry. (A) Percentage and (B) absolute number of total CD11c+ DCs. (C) Percentage and (D) absolute number of total OVA+ CD11c+ DCs. (E) Percentage and (F) absolute number of total CpG-ODN+ CD11c+ DCs. (G) Percentage and (H) absolute number of OVA+ or CpG-ODN+ simple positive and OVA+ CpG-ODN+ double positive within CD11c+ DCs. The data show the mean ± SEM of individual values (3-4 mice/treatment group in each experiment) and are representative of two independent experiments performed. n.s., not significant, *p < 0.05, **p < 0.01, ***p < 0.001.